Treatment group | Days post-treatment |
---|
0 | 30 | 60 | 84 |
---|
Fluralaner1 | No. of cats | 31 | 31 | 31 | 31 |
Mean SCORFAD Score3 | 7.5a,x | 2.7a,y | 1.3a,y | 1.1a,y |
SD | 8.39 | 3.96 | 1.77 | 1.47 |
Range | (0–28) | (0–18) | (0–7) | (0–6) |
% Reduction4 | Â | 63.6 | 82.8 | 85.3 |
Selamectin2 | No. of cats | 29 | 29 | 27 | 26 |
Mean SCORFAD Score3 | 7.7a,x | 5.6a,x | 3.2a,y | 3.4a,y |
SD | 10.34 | 8.85 | 4.73 | 3.90 |
Range | (0–50) | (0–35) | (0–21) | (0–13) |
% Reduction4 | Â | 26.9 | 58.1 | 56.5 |
- 1In the fluralaner group cats were treated once topically on day 0 (Bravecto® Topical solution; Merck Animal Health, Madison, NJ, USA)
- 2In the selamectin group cats were treated on day 0 and once between days 28–30 and 56–60 (Revolution®; Zoetis, Whippany, NJ, USA)
- 3Arithmetic mean SCORFAD lesion score
- 4{(Day 0 arithmetic mean SCORFAD score – day x arithmetic mean SCORFAD score) / day 0 arithmetic mean SCORFAD score)} × 100
- a,bArithmetic mean SCORFAD lesion scores in a column with like letter superscripts are not significantly different (P > 0.058; │t│ ≥ 0.21).
- x,yArithmetic mean SCORFAD lesion scores in a row with unlike letter superscripts are significantly different from day 0 (P < 0.001; │t│≥ 3.35; day 30 Selamectin vs baseline P = 0.13; t = 1.53)